Board of Directors
Douglas Bratton joined Aquestive’s Board as Chairman in 2004 and became a Board member in August 2018. He is the Founder, President, and CIO of Crestline Investors. Founded in 1997, Crestline is an institutional alternative investment management firm with approximately $9.2 billion of assets under management. Crestline specializes in credit and opportunistic investments, including financing restructuring solutions for mature private equity funds. In addition, the firm manages a multi-PM equity market-neutral hedge fund, and provides Beta and Hedging Solutions for Institutional clients. Headquartered in Fort Worth, Texas, the company maintains offices in New York City, Chicago, London, Toronto, and Tokyo. Mr. Bratton has been an investment professional specializing in alternative asset strategies since 1983 and has managed assets on behalf of the Bass family of Fort Worth, Texas, since 1988. Mr. Bratton received a BS from North Carolina State University in 1981 and a Masters of Business Administration with Honors from Duke University in 1984. Mr. Bratton serves on the Boards of Bounty Minerals Corporation and the Board of Visitors of Duke University’s Fuqua School of Business.
Keith J. Kendall
Chief Executive Officer and Director
Keith Kendall assumed the role of Chief Executive Officer at Aquestive in 2014 after serving as Co-president and Chief Operating Officer for the Company since 2011. Mr. Kendall also served as Executive Vice President and Chief Financial Officer of Aquestive since July 2006. From February 1999 to June 2006, he was the Vice President and Managing Director of the Americas for Hewlett Packard Financial Services. Mr. Kendall held a number of positions with AT&T Capital Corporation including President of AT&T Credit Corporation and NCR Credit Corporation from 1985 to 1998.
Dr. Gregory Brown
Gregory Brown joined Aquestive’s Board of Directors in March 2007. Dr. Brown is a co-founder and Vice Chairman at HealthCare Royalty Partners (HCR) and Chairman of the firm’s Strategic Advisory Board. Educated as a transplantation immunologist and trained as a thoracic and vascular surgeon, Dr. Brown practiced thoracic and vascular surgery in a community setting where he also founded and led an HMO. He brings particular expertise in the scientific, technical, clinical and medical evaluation of products as well as in healthcare systems and payor / reimbursement dynamics. He has been involved in sourcing, diligencing and closing more than $1 billion of royalty financings. Before co-founding HCR, Dr. Brown was a partner at Paul Capital Partners, where he co-managed that firm’s royalty investments as a member of the royalty management committee. Prior to beginning his principal investment career in 2003, Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. Dr. Brown holds a B.A. from Yale, an M.D. from SUNY Upstate Medical Center and an M.B.A. from Harvard Business School. He currently serves on the boards of Caladrius Biosciences, Faron Pharmaceuticals and Aquestive.
John Cochran has served on Aquestive’s Board of Directors since 2004. He has been a partner of Bratton Capital Management L.P. since October 1998, and is responsible for its private equity investments. Mr. Cochran is also responsible for the operations of Crestline Management, a credit-oriented alternative asset management platform. Prior to joining Bratton Capital Management L.P., he spent 10 years with KPMG focused primarily on audit and merger and acquisition due diligence. Mr. Cochran received his B.A. in Accounting from Texas Christian University and is also a licensed certified public accountant.
Chairman of the Board
Santo Costa joined Aquestive’s Board of Directors in 2015. His professional experience includes over 30 years in executive and senior operating management positions within the pharmaceutical, health care, and life sciences industries. Currently, Mr. Costa currently sits on the boards of Cytokinetics Inc. and Metabolon Inc. He has also served as a board member to numerous other public and private companies and charitable organizations. Mr. Costa is Of Counsel at the law firm Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan in Raleigh, N.C. In addition to his legal practice, Mr. Costa’s experience includes President, Chief Operating Officer, and Vice Chairman of Quintiles Transnational Corp. where during his tenure he had responsibility for all operating divisions and worldwide business development. He is also a nationally recognized speaker on leadership, as well as legal and policy issues affecting the pharmaceutical industry. Mr. Costa earned a B.S. in Pharmacy and his J.D. from St. John’s University.
Chairman of the Board
Nancy Lurker joined Aquestive’s Board of Directors in April 2018. Ms. Lurker currently serves as President and Chief Executive Officer of EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products. Before joining EyePoint Pharmaceuticals, she was Senior Vice President and Chief Marketing Officer of Novartis U.S. Pharmaceuticals Corporation and held senior positions at leading pharmaceutical companies including Pharmacia Corporation (now a part of Pfizer, Inc.) and Bristol-Myers Squibb Company. Ms. Lurker serves as a member of the board of directors of EyePoint Pharmaceuticals and the Cancer Treatment Centers of America, and is a member of the Novo A/S Advisory Group. She received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville.
James S. Scibetta
James Scibetta joined Aquestive’s Board of Directors in 2017. He is currently CEO of Maverick Therapeutics, a development stage immune-oncology company. Prior to Maverick, Mr. Scibetta was President of Pacira Pharmaceuticals (Nasdaq: PCRX) where he oversaw commercial and medical support activities, and directed commercial manufacturing, tech transfer, and R&D. Mr. Scibetta served as Pacira’s Chief Financial Officer from 2008 through May 2016 where he led its 2011 IPO and subsequent debt and equity financings. Prior to that, he was an executive with Bioenvision Inc. (Nasdaq: BIVN), a commercial stage oncology company acquired by Genzyme, and Merrimack Pharmaceuticals, an oncology-focused systems biology company. Earlier in his career he spent over a decade in investment banking where he was responsible for sourcing and executing transactions for a broad base of public and private healthcare and life sciences companies. He serves as a Board director and chairman of the audit committee of Matinas BioPharma (NYSE: MTNB). Mr. Scibetta received his B.S. in Physics from Wake Forest University and his MBA from the University of Michigan.
Corporate Governance Overview
The Board of Directors of Aquestive Therapeutics, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.
Governance Committees Composition
|Audit Committee||Compensation Committee||Nominating and Corporate Governance Committee|
|Douglas Bratton||Compensation Committee||Nominating and Corporate Governance Committee|
|Dr. Gregory Brown||Audit Committee||Nominating and Corporate Governance Committee|
|John Cochran||Compensation Committee||Nominating and Corporate Governance Committee|
|Santo Costa||Compensation Committee|
|Nancy Lurker||Audit Committee||Compensation Committee|
|James S. Scibetta||Audit Committee|
= Chairperson = Member